Natascia Bruni currently serves as Director of Research & Development and Qualified Person at Candioli Pharma S.r.l., a pharmaceutical company based in Beinasco (Turin, Italy), specializing in two main areas: the human sector (notably in the production of antiparasitic treatments, including the well-known MOM product) and the veterinary sector (offering a wide range of health products for companion animals, athletic horses, and ornithology).

Dr. Bruni holds a degree in Industrial Chemistry, a PhD from the University of Turin, and completed postdoctoral studies at the High Synthesis School in Gargnano. She has specialized in the research and development of innovative health products for companion animals, particularly dietary supplements and advanced therapeutic solutions.

Dr. Bruni is a member of the Research, Development, and Innovation Committee of Federchimica, where she actively contributes to promoting innovation within the chemical and pharmaceutical sectors in Italy.

Under her leadership, Candioli Pharma participated in the 2024 Sustainability Award, highlighting the company’s commitment to sustainable and responsible practices in the pharmaceutical field.

Scientific Activities

Dr. Bruni has an extensive scientific and research background, with a focus on pharmaceutical chemistry, biotechnology, and veterinary medicine. She is co-author of numerous scientific publications in international journals. Her main contributions include:

• Studies on the antimicrobial activity of peptides derived from lactoferrin, with potential applications in both human and veterinary medicine.
• Research on nanostructured delivery systems aimed at enhancing therapeutic efficacy against leishmaniasis.
• Investigations into the use of dietary supplements for managing hyperphosphatemia in small animals with chronic kidney disease.
• Analysis of the effects of probiotic strains on nutritional and microbiological parameters in dogs, especially Lactobacillus acidophilus D2/CSL.
• Patent activity related to novel compositions based on lactoferrin hydrolysates and phytoactive substances for treating infections and inflammation in veterinary dermatological and otological applications.